GPhA’s New VP-Regulatory Sciences Has Expertise In Generic Injectable Business
This article was originally published in The Pink Sheet Daily
Executive Summary
During nine years at Ben Venue, Gaugh was responsible for strategic planning, financial management, business development, marketing and sales for the company’s $500 million branded generic injectable business, which is now struggling with manufacturing challenges.
You may also be interested in...
Drug Shortages Give Ben Venue Relief In FDA Consent Decree
The consent decree permits the company to continue to manufacture more than 100 drugs, 20 of which are on FDA’s current drug shortage list. Ben Venue must prove compliance with good manufacturing practice requirements before it can manufacture its other drugs.
Drug Shortages Give Ben Venue Relief In FDA Consent Decree
The consent decree permits the company to continue to manufacture more than 100 drugs, 20 of which are on FDA’s current drug shortage list. Ben Venue must prove compliance with good manufacturing practice requirements before it can manufacture its other drugs.
People In The News: Tracking The Latest Industry Personnel Moves
New top leadership at Critical Path Institute, NeurogesX; Former CMS Acting Administrator Frizzera joins FaegreBD Consulting. More personnel moves in this month’s column.